TAK-981 is a first-in-class inhibitor of the SUMOylation enzymatic cascade being developed for the treatment of multiple myeloma.
SparkCures ID | 409 |
---|---|
Developed By | Takeda Oncology |
Generic Name | TAK-981 |
Treatment Classifications |
|
There are no resources, links or videos to display for this treatment.